Hallux Incis A Clinical Stage Pharmaceutical Company Based In Californiafounded In 2012The Company Focuses On Developing Treatments For Onychomycosisa Common Fungal Nail Infection That Affects Millions Globallyhallux Incaims To Advance New Treatment Options For This Condition The Company S Flagship Product Is The Hallux Subungual Gelhsg A Topical Terbinafine Formulation Designed For Direct Application Onto The Nail Bedthis Innovative Approach Targets The Site Of Infection More Effectively Than Traditional Topical Treatmentshallux Is Also Working On An Investigational Micro Insert For Subungual Deliveryspecifically For Distal Lateral Subungual Onychomycosis Hallux Incis Actively Engaged In Clinical Trials For Its Products And Has Achieved Significant Milestones In Its Research Effortsthe Company Secured $9 4 Million In Series A 2 Financing In Early 2022 To Support Its Ongoing Studiesmark Taylor Serves As The President And Ceoleading A Team Dedicated To Improving Treatment Options For Patients Suffering From Onychomycosis
No conferences found for this company.
| Company Name | Hallux Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
